Viral Hemorrhagic Fever Clinical Trials

Find Viral Hemorrhagic Fever Clinical Trials Near You

A Randomized, Double-blind, Placebo-controled, Phase 2a Trial Evaluating the Safety and Initial Efficacy of Resomelagon in Patients With Dengue Infection

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are: Is Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Patients who are 18 to 65 years old;

• Able to understand study procedures and give informed consent;

• Presents with more than 36 and less than 84h since symptoms onset;

• Symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test.

Locations
Other Locations
Brazil
Clinical Research Unit
RECRUITING
Belo Horizonte
Centro Integrado de Pesquisa
NOT_YET_RECRUITING
São José Do Rio Preto
Contact Information
Primary
Pedro RJ Almeida, MD MSc
pedrojesus@ufmg.br
+5531995166160
Time Frame
Start Date: 2026-03-20
Estimated Completion Date: 2027-12
Participants
Target number of participants: 120
Treatments
Experimental: Resomelagon
Resomelagon, 100mg, orally, once daily plus standard treatment
Placebo_comparator: Placebo
Placebo plus standard treatment
Related Therapeutic Areas
Sponsors
Leads: Federal University of Minas Gerais
Collaborators: Instituto Nacional de Ciência e Tecnologia em Dengue (INCT em Dengue)

This content was sourced from clinicaltrials.gov